Phase 2 × Lymphoma × Cytarabine × Clear all
NCT00004192 2023-12-27

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

University of Nebraska

Phase 2 Completed
60 enrolled
NCT00080886 2023-10-06

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

University of Nebraska

Phase 2 Completed
68 enrolled
NCT00005985 2017-11-29

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
213 enrolled
NCT00005998 2017-11-29

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT00238368 2017-11-06

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
59 enrolled
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT00005601 2016-12-07

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Completed
58 enrolled
NCT00002718 2015-12-23

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
31 enrolled